Limited data has been reported related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. Depressed level of consciousness, circulatory collapse and shock has been reported.
The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilization of the circulatory condition is of prime importance. If hypotension occurs, supportive treatment should be instituted, the patient should be placed in a supine position and blood volume correction should be undertaken.
Valsartan is not reported to be removed from the plasma by hemodialysis.
Valsartan was not reported for grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets (60 and 31 times, respectively, the maximum recommended human dose on a mg/m2 basis), except for salivation and diarrhea in the rat and vomiting in the marmoset at the highest dose .